Enalapril Management in CKD G3a Patients (eGFR ≈ 57 mL/min/1.73 m²)

Continuation and Dosing

Enalapril should be continued at the current dose and renal function re‑checked within 2–4 weeks, because patients with CKD G3a still derive hypertension control and kidney‑protective benefits from ACE‑inhibition. 1
ACE‑inhibitor therapy remains appropriate even when eGFR falls below 30 mL/min/1.73 m²; an eGFR of 57 mL/min/1.73 m² is well within the safe continuation range. 2
The usual enalapril dose range (5–40 mg daily) is acceptable for creatinine clearance > 30 mL/min; no dose reduction is required for the patient described. 3

Serum creatinine, serum potassium, and blood pressure should be measured within 2–4 weeks after any dose change or when therapy is newly initiated. 4
Enalapril should be maintained unless serum creatinine rises > 30 % within 4 weeks of initiation or dose escalation. 1

Reduce or stop enalapril only if symptomatic hypotension persists despite appropriate management. 5
Reduce or stop enalapril only if hyperkalemia remains uncontrolled after applying potassium‑lowering strategies. 5
Reduce or stop enalapril if serum creatinine increases > 30 % within 4 weeks of starting or increasing the dose. 2
Reduce or stop enalapril if eGFR falls below 15 mL/min/1.73 m² accompanied by uremic symptoms. 2

Measure urine albumin‑to‑creatinine ratio (ACR) to stratify risk and guide adjunctive therapy. 3
If ACR ≥ 200 mg/g (≥ 20 mg/mmol), add an SGLT2 inhibitor (KDIGO 1A recommendation) for additional renal and cardiovascular protection. 1
If ACR 30–200 mg/g, consider adding an SGLT2 inhibitor (KDIGO 2B recommendation for eGFR 20–45 mL/min/1.73 m²; reasonable at eGFR 57). 2
Titrate enalapril to the highest tolerated dose (up to 40 mg daily) to achieve the renoprotective effect demonstrated in clinical trials. 4

Hyperkalemia should be addressed with potassium‑lowering measures rather than discontinuing enalapril. 1
Implement dietary potassium restriction when hyperkalemia develops. 2
Monitor serum potassium regularly, especially within 2–4 weeks after any dose adjustment. 3

Do not discontinue enalapril prematurely for modest creatinine rises < 30 % or expected eGFR declines; these changes are often benign and associated with improved outcomes. 1
Do not combine enalapril with an ARB or a direct renin inhibitor, as dual RAS blockade increases adverse events without added benefit. 5